Organization | Azienda Ospedaliera Sant'Andrea, Roma

Azienda Ospedaliera Sant'Andrea, Roma Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Rome Italy (2001)

Organization Overview

First Clinical Trial

2012

NCT01784549

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Azienda Ospedaliera "Sant'Andrea" | Onlus S. Andrea | Ospedale Sant'Andrea

Active Ingredients

Drugs in Phase 4 Trials (2)

mitomycin (mutamycin) (1 trial)

palmitoylethanolamide (1 trial)

Drugs in Phase 3 Trials (2)

magnesium sulfate (Tis-U-Sol) (1 trial)

sodium picosulfate (1 trial)

Drugs in Phase 2 Trials (12)

afatinib (gilotrif) (1 trial)

cisplatin (platinol) (1 trial)

docetaxel (taxotere) (1 trial)

erlotinib (tarceva) (1 trial)

gefitinib (iressa) (2 trials)

gemcitabine (gemzar) (1 trial)

lactobacillus rhamnosus (1 trial)

methylprednisolone (medrol) (1 trial)

pemetrexed (alimta) (1 trial)

thymalfasin (zadaxin) (1 trial)

tocilizumab (actemra) (1 trial)

vinorelbine (navelbine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Lung Neoplasms (Phase 2)

Ulcer (Phase 2)

Urinary Bladder Neoplasms (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 16